A patient with worsening renal function, hypercalcemia, and anemia is experiencing increased fatigue, bone pain, and difficulty ambulating. Which intervention should the nurse prioritize to address the patient's immediate clinical needs?

B) Increase the patient's fluid intake to improve renal function.

A) Administer bisphosphonates as prescribed to manage hypercalcemia.

B) Increase the patient's fluid intake to improve renal function.

C) Administer erythropoietin to address anemia.

D) Implement non-pharmacological pain management techniques.

A patient with worsening renal function, hypercalcemia, and severe bone pain is admitted to your unit. What is the priority nursing intervention to address both the renal impairment and hypercalcemia?

B) Encourage oral fluid intake to promote renal function.

A) Administer prescribed bisphosphonates to lower calcium levels.

B) Encourage oral fluid intake to promote renal function.

C) Implement a pain management plan involving opioid analgesics.

D) Monitor the patient's respiratory status closely.

A patient with multiple myeloma has undergone recent diagnostic testing revealing significant plasma cell infiltration, elevated M-protein levels, multiple lytic bone lesions, and vertebral compression fractures. Which nursing intervention is most appropriate to address the patient's risk for hypercalcemia?

A) Encourage increased fluid intake and monitor urine output.

B) Implement fall precautions and provide assistive devices.

C) Educate the patient on dietary calcium restrictions.

D) Schedule regular physical therapy sessions to enhance mobility.

A patient with multiple myeloma has undergone recent diagnostic testing revealing a 30% plasma cell infiltration in the bone marrow, increased M-protein levels, and multiple lytic bone lesions. What is the most appropriate nursing intervention to address the patient's bone pain and mobility issues?

B) Administer prescribed bisphosphonates to reduce bone pain.

A) Encourage bed rest to prevent further injury.

B) Administer prescribed bisphosphonates to reduce bone pain.

C) Provide high-impact exercises to strengthen bone integrity.

D) Advise the patient to increase calcium intake to strengthen bones.

A patient with multiple myeloma undergoing chemotherapy presents with new-onset fatigue, mild confusion, and worsening renal function. Which nursing intervention is most critical to implement first?

B) Initiate intravenous hydration as ordered.

A) Administer prescribed oral calcium supplements.

B) Initiate intravenous hydration as ordered.

C) Educate the patient on the importance of monitoring fluid intake.

D) Schedule a renal ultrasound to assess kidney function.

A patient undergoing aggressive chemotherapy for multiple myeloma presents with increased fatigue, mild confusion, and laboratory evidence of hypercalcemia and renal impairment. Which nursing intervention should be prioritized to address these clinical findings?

A) Administering prescribed bisphosphonate therapy to lower calcium levels

B) Initiating a high-protein diet to improve anemia and energy levels

C) Encouraging oral fluid intake to promote renal clearance

D) Providing cognitive exercises to improve mental status

A patient with hypercalcemia and multiple myeloma is experiencing cognitive fluctuations and renal impairment, with recent laboratory findings showing elevated serum creatinine and blood urea nitrogen levels. Based on these findings, what is the most appropriate nursing intervention to prioritize at this time?

C) Encourage fluid intake to promote renal perfusion and calcium excretion.

A) Administer an antiemetic to address potential nausea from chemotherapy.

B) Implement seizure precautions to prevent injury during episodes of confusion.

C) Encourage fluid intake to promote renal perfusion and calcium excretion.

D) Educate the patient about the importance of medication adherence to prevent further complications.

A patient with hypercalcemia and renal impairment is experiencing intermittent confusion and an irregular heart rhythm confirmed by ECG as premature atrial contractions. What is the priority nursing intervention for this patient?

B) Monitor intake and output closely to assess renal function and fluid status

A) Administer prescribed calcium supplements to prevent further weakness

B) Monitor intake and output closely to assess renal function and fluid status

C) Educate the patient about reducing dietary calcium intake to manage hypercalcemia

D) Prepare the patient for immediate dialysis to address rising creatinine levels

A patient with multiple myeloma is experiencing worsening cognitive function and has been diagnosed with hepatic encephalopathy and renal failure. Which nursing intervention is the priority to address the patient's current condition?

B) Prepare the patient for dialysis to manage renal failure.

A) Administer lactulose as prescribed to reduce ammonia levels.

B) Prepare the patient for dialysis to manage renal failure.

C) Educate the patient on dietary modifications to prevent further renal damage.

D) Monitor cardiac rhythm and administer antiarrhythmic medication as prescribed.

A patient with multiple myeloma is experiencing worsening cognitive function and has been diagnosed with hepatic encephalopathy and renal failure. Dialysis has been initiated, and the chemotherapy dosage has been reduced. Which nursing intervention should be prioritized to address the patient's current condition?

A) Administer lactulose to manage hepatic encephalopathy.

B) Monitor for signs of infection related to the dialysis catheter.

C) Educate the patient about dietary restrictions related to renal failure.

D) Assess for signs of bleeding due to thrombocytopenia from chemotherapy.

Multiple Myeloma - Nursing Case Study

Pathophysiology

• Primary mechanism: Multiple Myeloma is characterized by the clonal proliferation of malignant plasma cells in the bone marrow. These abnormal cells produce excessive monoclonal immunoglobulins, leading to impaired normal antibody production and immune dysfunction.

• Secondary mechanism: The overproduction of monoclonal proteins can cause renal damage due to protein precipitation and tubular obstruction. Additionally, the proliferation of plasma cells leads to osteoclast activation, resulting in bone resorption and lesions.

• Key complication: The accumulation of myeloma cells and their byproducts can lead to hypercalcemia, anemia, and increased risk of infections, significantly impacting patient health and requiring vigilant nursing care.

Patient Profile

Demographics:

62-year-old male, retired construction worker

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Osteoporosis

• Current medications: Metformin, Lisinopril, Calcium supplements, Dexamethasone

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing fatigue and bone pain

• Key symptoms: Anemia, renal impairment, recurrent infections, hypercalcemia, lytic bone lesions

• Vital signs: Blood pressure 145/90 mmHg, Heart rate 98 bpm, Respiratory rate 20 breaths per minute, Temperature 37.8°C (100°F)

Section 1

Change in Patient Status:

A week into the hospital stay, the patient's condition has shown some concerning changes. The fatigue has intensified, and the bone pain, previously managed with analgesics, has become more severe, particularly in the lower back and ribs. The patient reports difficulty in ambulating due to the pain, which has further decreased his mobility. His vital signs reveal a persistent increase in blood pressure, now 150/95 mmHg, possibly exacerbated by his pain levels. His heart rate remains slightly elevated at 102 bpm, and he is experiencing mild shortness of breath on exertion, with a respiratory rate of 22 breaths per minute.

Laboratory results indicate a worsening of renal function, with serum creatinine levels rising to 2.3 mg/dL from a baseline of 1.8 mg/dL, suggestive of progressing renal impairment. His calcium levels have increased to 11.5 mg/dL, further contributing to his fatigue and muscle weakness. Hemoglobin levels have decreased to 9.0 g/dL, indicating worsening anemia, which could be a result of both the disease process and renal insufficiency. Additionally, a recent urinalysis suggests proteinuria, likely due to the nephrotoxic effects of the monoclonal proteins.

These developments indicate a need for a reassessment of the current management plan. The escalating renal impairment and hypercalcemia require urgent intervention to prevent further complications. The healthcare team should consider adjusting the patient's medication regimen, potentially incorporating bisphosphonates to manage the hypercalcemia and more aggressive hydration to support renal function. Pain management strategies need to be revisited, possibly integrating non-opioid analgesics or adjunct therapies to optimize mobility and quality of life. Close monitoring of the patient's fluid balance and electrolyte levels will be crucial in guiding ongoing treatment decisions.

Section 2

New Diagnostic Results:

Following the concerning changes in the patient's clinical presentation, additional diagnostic tests were conducted to gain further insight into his condition. A bone marrow biopsy was performed to assess the extent of plasma cell infiltration, revealing a significant increase in plasma cells, now accounting for 30% of the marrow, indicative of disease progression. This finding correlates with the patient's worsening anemia and elevated calcium levels. In conjunction with the biopsy, serum protein electrophoresis showed a marked increase in M-protein levels to 4.5 g/dL, further confirming the increased burden of the disease.

An advanced imaging study, a whole-body low-dose CT scan, was also carried out to evaluate the extent of bone involvement. The results highlighted multiple lytic lesions, notably in the lumbar spine and ribs, which correlate with the patient's intensifying bone pain and reduced mobility. These lesions suggest increased bone turnover and contribute to the patient's hypercalcemia. Additionally, the imaging revealed early signs of vertebral compression fractures in the lower spine, explaining the exacerbated back pain and ambulatory difficulties.

These new diagnostic findings provide critical information for refining the treatment strategy. The escalation in both plasma cell infiltration and M-protein levels indicates a need for more aggressive chemotherapy regimens to control the disease. The identification of vertebral compression fractures underscores the importance of integrating orthopedic and pain management strategies, potentially involving vertebroplasty or kyphoplasty, alongside pharmacological interventions. Monitoring the patient's response to these tailored interventions will be essential in the upcoming days to manage the multiple complications effectively and improve his overall condition.

Section 3

Following the implementation of a more aggressive chemotherapy regimen, the patient was closely monitored for his response to the interventions. Initially, there was a slight improvement in his anemia, with hemoglobin levels rising from 9.0 g/dL to 9.5 g/dL over the first week. However, the patient began to exhibit signs of renal impairment, a common complication in multiple myeloma due to elevated calcium and protein levels. Serum creatinine levels increased from 1.2 mg/dL to 2.0 mg/dL, and blood urea nitrogen rose to 28 mg/dL, indicating a decline in renal function.

Clinically, the patient also reported new-onset fatigue and mild confusion, which were further compounded by worsening hypercalcemia, with calcium levels climbing to 12.5 mg/dL. This change necessitated the immediate initiation of intravenous hydration and bisphosphonate therapy to address the hypercalcemia and support renal function. Additionally, the healthcare team considered the possibility of acute kidney injury secondary to light chain deposition, warranting further evaluation through urine protein electrophoresis and renal ultrasound.

The emergence of renal complications and neurocognitive changes prompted a multidisciplinary approach to his care, involving nephrology for renal support and potential dialysis planning, alongside continued oncology oversight for chemotherapy adjustments. As the team worked to stabilize these conditions, they also prepared for potential adjustments in the patient's therapeutic strategy, mindful of balancing disease control with the management of adverse effects. Continuous assessment of renal function and mental status was prioritized, setting the stage for subsequent evaluations that would determine the next steps in his treatment journey.

Section 4

As the healthcare team continued to manage the patient's condition, a significant change in his status emerged. Despite the interventions for hypercalcemia, the patient developed increasing weakness and was unable to ambulate without assistance. His vital signs showed a mild tachycardia with a heart rate of 102 beats per minute and a blood pressure of 140/90 mmHg, suggesting a potential compensatory response to dehydration or ongoing electrolyte imbalance. On further examination, the patient exhibited an irregular heart rhythm. An ECG confirmed the presence of premature atrial contractions, likely secondary to electrolyte disturbances.

In parallel, the patient's laboratory results revealed a concerning trend. The serum creatinine level rose further to 2.5 mg/dL, and the blood urea nitrogen increased to 35 mg/dL, indicating ongoing renal impairment. Urine protein electrophoresis confirmed significant monoclonal proteinuria, consistent with light chain deposition disease. Additionally, a renal ultrasound showed evidence of nephrocalcinosis, reinforcing the need for aggressive management of calcium levels and renal support. Given these findings, the nephrology team expedited planning for potential dialysis, while the oncology team reassessed the chemotherapy regimen, weighing the risks of continued renal deterioration against the benefits of aggressive myeloma control.

These developments highlighted the complexity of balancing treatment efficacy with the management of emerging complications. The patient’s cognitive status fluctuated, with intermittent confusion that necessitated close neurological monitoring. The healthcare team discussed the potential need for a revised treatment protocol, considering options such as reducing the chemotherapy dose or introducing renal-protective strategies. This phase of the patient’s journey underscored the critical need for ongoing, dynamic care coordination, as the team worked to stabilize his condition and prevent further complications.

Section 5

As the healthcare team continued to monitor the patient closely, new complications arose that required immediate attention. Over the following days, the patient's cognitive status worsened significantly, with episodes of confusion becoming more frequent and severe. A neurological evaluation was conducted, revealing asterixis, suggesting possible hepatic encephalopathy or a further decline in renal function contributing to uremia. This necessitated an urgent review of his medication regimen and electrolyte management, given the risk of exacerbating neurological symptoms.

Simultaneously, new diagnostic results indicated a further deterioration in renal function. The patient's serum creatinine level climbed to 3.0 mg/dL, and blood urea nitrogen increased to 45 mg/dL. These findings, coupled with the patient's declining cognitive function, prompted the nephrology team to move forward with renal replacement therapy. Preparation for dialysis was expedited, with a temporary venous catheter placed for immediate access. The decision to initiate dialysis was supported by the patient's increasingly irregular heart rhythm, with more frequent episodes of premature atrial contractions, likely aggravated by ongoing electrolyte imbalances.

The oncology team, in response to these developments, re-evaluated the patient's chemotherapy plan. A multidisciplinary meeting concluded that a reduction in chemotherapy dosage was necessary to minimize further renal damage while still attempting to control the progression of multiple myeloma. The team also implemented renal-protective strategies, including the administration of bisphosphonates to manage hypercalcemia more effectively and avoid calcium-related complications. These adjustments aimed to stabilize the patient's condition, highlighting the importance of integrated care in managing complex cases such as this. The team remained vigilant, closely monitoring the patient's response to these interventions and preparing for potential further complications.